A Phase I Study Assessing the Safety, Tolerability and Pharmacokinetics of AZD1775 in Combination With MEDI4736 in Patients With Advanced Solid Tumours

Trial Profile

A Phase I Study Assessing the Safety, Tolerability and Pharmacokinetics of AZD1775 in Combination With MEDI4736 in Patients With Advanced Solid Tumours

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs AZD-1775 (Primary) ; Durvalumab
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 06 Jul 2017 Planned End Date changed from 30 Mar 2018 to 31 May 2018.
    • 06 Jul 2017 Planned primary completion date changed from 30 Mar 2018 to 31 May 2018.
    • 01 May 2017 Planned number of patients changed from 42 to 55.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top